CGON compared with AKTS: revenue, margins and what each company keeps, and the suppliers and customers both name

CGONCG Oncology, Inc.

Mkt capRevenueRevenue

AKTSAktis Oncology, Inc.

Mkt capRevenueRevenue

Compare

CGONCG Oncology, Inc.

AKTSAktis Oncology, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

CGON

0 of 3at or beyond implied

Reportimpliedrealized× implied

Q3 FY26—▲+17.27%—

Q2 FY26±14.5%▲+3.36%×0.23

May 8 '26±9.9%▲+0.64%×0.06

Q1 FY26±10.7%▲+4.79%×0.45

AKTS3 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±17.0%▲+4.79%×0.28

May 12 '26—▲+7.99%—

= impliedCGON realized, solidAKTS realized, hatchedOne scale, both sides: full bar = 18%× = |realized| ÷ impliedspan: CGON 252d · AKTS 136dSource: market data

Q1 FY26—▲+8.16%—

CGONCG Oncology, Inc.

74.64▼−1.78%· post 74.40· delayed

Mkt cap$6.6BRevenue$2MQ3 FY26

AKTSAktis Oncology, Inc.

16.33▲+3.23%· post 16.33· delayed

After hoursNov 9 '26delayed

Mkt cap$905.3MRevenue$3MQ2 FY26

Compare

After hoursNov 9 '26delayed

CGONCG Oncology, Inc.

AKTSAktis Oncology, Inc.

74.64▼−1.78%post 74.40delayed

Price

16.33▲+3.23%post 16.33delayed

$6.6B

Mkt cap

$905.3M

Q3 FY26$2M

Revenue

$3MQ2 FY26

CGON74.64▼−1.78%vsAKTS16.33▲+3.23%After hoursNov 9 '26delayed